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Abstract
Introduction: Rheumatoid arthritis is an autoimmune disease in which joint inflammation leads to progressive
cartilage and bone erosion. Matrix metalloproteinases (MMPs) implicated in homeostasis of the extracellular matrix
play a central role in cartilage degradation. However, the role of specific MMPs in arthritis pathogenesis is largely
unknown. The aim of the present study was to investigate the role of Mmp-8 (collagenase-2) in an arthritis model.
Methods: Arthritis was induced in Mmp8-deficient and wildtype mice by K/BxN serum transfer. Arthritis severity
was measured by a clinical index and ankle sections were scored for synovial inflammation, cartilage damage and
bone erosion. cDNA microarray analysis, real-time PCR and western blot were performed to identify differential
changes in gene expression between mice lacking Mmp8 and controls.
Results: Mmp8 deficiency increased the severity of arthritis, although the incidence of disease was similar in
control and deficient mice. Increased clinical score was associated with exacerbated synovial inflammation and
bone erosion. We also found that the absence of Mmp8 led to increased expression of IL-1b, pentraxin-3 (PTX3)
and prokineticin receptor 2 (PROKR2) in arthritic mice joints.
Conclusions: Lack of Mmp-8 is accompanied by exacerbated synovial inflammation and bone erosion in the K/
BxN serum-transfer arthritis model, indicating that this Mmp has a protective role in arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by joint inflammation and progressive
destruction of cartilage and bone. Current knowledge of
joint destruction indicates that matrix metalloprotei-
nases (MMPs) have a pivotal role in cartilage damage.
Articular cartilage is composed of the extracellular
matrix and a small number of chondrocytes. Aggrecan
and fibrillar type II collagen are the main components
of the cartilage extracellular matrix. In RA, depletion of
proteoglycans and the subsequent degradation of col-
lagen lead to destruction of articular cartilage. The
metalloproteinases induced by IL-1b, TNF, IL-17 and
IL-18 are pivotal in this process [1-4].
Multiple pieces of evidence support the relevance of
MMPs in the pathogenesis of RA. Several MMPs are
highly expressed in the synovial lining and sublining of
RA patients and high levels of these proteins have been
detected in their sera and synovial fluid [5-7]. Specifi-
cally, the high serum levels of MMP-1 and MMP-3 have
been proposed as predictors of joint destruction [8].
The role of a few of the MMPs has been analyzed in
experimental arthritis models using deficient mice, and
the results were variable depending on the MMP ana-
lyzed. The effect of Mmp-2 was analyzed in an anti-
body-induced arthritis model [9]. The Mmp2-deficient
mice showed significantly exacerbated arthritis com-
pared with wildtype mice, suggesting a suppressive role
of Mmp-2 in this model. In contrast, the absence of
Mmp-9 was associated with reduced severity of arthritis,
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indicating the need of Mmp-9 for the development of
arthritis [9]. The role of Mmp-3 was analyzed in anti-
gen-induced arthritis and collagen-induced arthritis
models [10,11], and a similar incidence and severity of
arthritis was displayed by Mmp3-deficient and control
mice in both arthritis models. This range of results indi-
cates the need to investigate the specific role of indivi-
dual MMPs in the pathogenesis of RA to identify
specific targets.
MMP-8 (collagenase-2) is mainly produced by neutro-
phils, although it is also expressed by a wide range of
cells including chondrocytes [12] and synovial fibro-
blasts [13]. MMP-8 is a potent collagenolytic enzyme
that is involved in the pathogenesis of several inflamma-
tory conditions. Van Lint and colleagues showed that
Mmp8-deficient mice were protected against TNF-
induced lethal hepatitis [14]. Livers of knockout mice
did not show the massive influx of neutrophils seen in
wildtype mice, probably due to the functional link
between Mmp-8 and lipopolysaccharide-induced CXC
chemokine, a PMN chemokine. Their work suggests
that Mmp-8 is involved in lipopolysaccharide-induced
CXC chemokine release and, in turn, in neutrophil
recruitment during inflammation. Likewise, the pivotal
role of MMP-8 in lipopolysaccharide-induced CXC che-
mokine, CXCL5 and CXCL8 activation was recently
reported [15]. An increased neutrophil accumulation
was found, however, in induced skin carcinomas and
during wound healing in mice lacking Mmp8 [16]. Also,
Mmp8-deficient mice developed more severe inflamma-
tion than wildtype mice in an allergen-induced airway
inflammation model and showed more neutrophils in
the bronchoalveolar lavage fluid [17]. Overall, these stu-
dies indicate that the role of MMP-8 in the inflamma-
tory process is complex and difficult to predict in
advance, probably due to specific features of the tissue
and stimulus involved in each situation.
Several findings suggest that MMP-8 has a role in
RA pathogenesis. It is expressed in serum and synovial
fluid from patients with RA. Fibroblast-like synoviocyte
cultures from RA patients produce MMP-8 after TNFa
stimulation [6,13]. In addition, MMP-8 regulates the
activity of several chemokines implicated in RA
[18,19]. In the present study we have therefore investi-
gated the impact of Mmp8 deficiency in the induced
arthritis using the K/BxN serum transfer model. We
have also performed a cDNA microarray analysis to
investigate differences in the transcriptional profiles
from Mmp8-deficient and wildtype mice. According to
our data, we conclude that Mmp-8 has a protective
role in arthritis derived from the ability of this metallo-
protease to induce changes in a series of inflammatory
mediators.
Materials and methods
Mice
Mice lacking Mmp8 have been previously described [19]
and the KRN T-cell-receptor transgenic mice were a
kind gift from C Benoist and D Mathis (Harvard Medi-
cal School, Boston, MA, USA; and IGBMC, Strasbourg,
France). NOD and C57BL/6 mice were purchased from
Charles River (Barcelona, Spain).
Mmp8+/- (mixed C57BL/6 × 129Sv background) mice
were backcrossed into the C57BL/6 background for 12
breedings. Mmp8+/- mice were then intercrossed to gen-
erate the Mmp8-/-, Mmp8+/- and Mmp8+/+ mice used
for arthritis induction.
Genotypes were assessed by PCR of tail DNA. PCR
reactions were made using DNA 100 ng, dNTPS 200
μM (Roche, Mannheim, Germany), specific primers 0.5
μM, MgCl2 1.5 mM, PCR buffer reaction (Roche) and
Taq DNA polymerase 0.5 U (Roche). Amplification
was performed using the following conditions: 94°C for
2 minutes, 30 cycles at 94°C for 1 minute, 60°C for 1
minute and 72°C for 1 minute, and a final cycle of
elongation at 72°C for 4 minutes. The size of the
amplified DNA products was determined in a 1.5%
agarose gel in Tris-acetate-EDTA. Amplification of
the wildtype allele was carried out with the primer
pairs 5’-GTGGATGAATCCCCAGACTC-3’ (forward)
and 5’-CAAGCAATCAATTCCGGTCT-3’ (reverse)
[EMBL: AK089234]; and for amplification of the
knockout allele, the primers 5’-GTGGATGAATCCC-
CAGACTC-3’ [EMBL: AK089234] (forward) and 5’-
TCGCCTTCTTGACGAGTTCT-3’ (reverse) [GenBank:
DQ890917.2] were used.
K/BxN mice that spontaneously develop arthritis were
generated by crossing KRN T-cell-transgenic mice with
NOD mice, as previously described [20].
Mice were maintained in the conventional mouse
facility of the Medical School of the University of San-
tiago de Compostela. Animal care was in compliance
with Spanish regulations on the protection of animals
used for experimental and other scientific purposes
(Real Decreto 223/1998). The experimental protocols
were approved by the Animal Care and Use Committee
of the University of Santiago de Compostela.
Generation of serum-transferred arthritis and clinical
scoring
K/BxN serum was collected from 4-week-old to 8-week-
old arthritic K/BxN mice. The serum samples were
pooled and stored at -80°C until use. Arthritis was
induced by transfer of this pool of sera in 6-week-old to
8-week-old mice in three different experimental groups.
In Group 1, arthritis was induced in 10Mmp8-/- mice, 10
Mmp8+/+ mice, and 10 Mmp8+/- mice by intraperitoneal
García et al. Arthritis Research & Therapy 2010, 12:R224
http://arthritis-research.com/content/12/6/R224
Page 2 of 12
injection of 200 μl K/BxN serum on days 0 and 2. These
mice were killed on day 14 after serum transfer.
In Group 2, arthritis was induced in 17 Mmp8-/- mice
and 17 control mice (Mmp8+/+ and Mmp8+/-) by intra-
peritoneal injection on days 0 and 2 of 100 μl K/BxN
serum. These mice were killed for histological assess-
ment on day 9 after serum transfer.
In Group 3, arthritis was induced in nine Mmp8-/-
male mice and nine Mmp8+/+ male mice by injection on
days 0 and 2 of 150 μl K/BxN mice serum. These mice
were killed for RNA and protein isolation on day 7 after
serum transfer.
Arthritis was assessed in each of the four limbs every
other day by two blinded observers, using a semiquanti-
tative clinical score (0 = no swelling; 1 = slight swelling
and erythema of the ankle, wrist or digits; 2 = moderate
swelling and erythema; 3 = severe swelling and
erythema; and 4 = maximal inflammation with joint
rigidity). The maximum possible score was 16 per
mouse.
Histological analysis
Hind limbs were prepared for histology by dissecting the
skin and muscle, and then sectioning ankle joints. Speci-
mens were fixed for 24 hours and demineralized in PBS-
0.5 M ethylenediamine tetraacetic acid for 10 days. Ankle
joints were embedded in paraffin and sections were cut
and stained with hematoxylin and eosin for evaluation of
inflammation and bone erosion, as previously described
[21]. For analysis of the damage in cartilage, ankle sec-
tions were stained with Toluidine blue and Safranin-O
following the standard methodology. To determinate
osteoclast activity, staining for tartrate-resistant acid
phosphatase (TRAP) was performed using the Acid Phos-
phatase, Leukocyte (TRAP) kit (Sigma, St Louis, MO,
USA) following the manufacturer’s instructions. Synovial
inflammation was scored as previously described [21]:
0 = no inflammation; 1 = slight thickening of synovial
cell layer and/or some inflammatory cells in the sublin-
ing; 2 = thickening of synovial lining and moderate infil-
tration of the sublining; 3 = thickening of synovial lining
and marked infiltration; and 4 = thickening of synovial
lining and severe infiltration.
Cartilage damage was evaluated following a 0 to 4
scale, as previously described [21]: 0 = normal cartilage;
1 = cartilage surface irregularities and loss of metachro-
masia adjacent to superficial chondrocytes; 2 = fibrilla-
tion of cartilage with minor loss of surface cartilage; 3 =
moderate cartilage abnormalities including loss of super-
ficial cartilage and moderate multifocal chondrocyte
loss; and 4 = marked cartilage destruction with exten-
sion of fissures close to subchondral bone.
Bone erosion was scored on a 0 to 4 scale, as pre-
viously described [22]: 0 = normal bone; 1 = small areas
of resorption; 2 = more numerous areas of resorption;
3 = obvious resorption; and 4 = full-thickness resorption
areas in the bone.
Osteoclast activity was evaluated following a scale
from 0 to 4 regarding TRAP staining, as previously
described [23]: 0 = no staining; 1 = rare positive cells;
2 = some foci of positive cells; 3 = multiple foci; and
4 = diffuse staining. All scores were performed blind
with respect to the mouse group.
Microarray analysis
Total RNA was obtained from ankle joints of three male
mice from each of the following groups: Mmp8+/+
arthritic mice, Mmp8+/+ control mice, Mmp8-/- arthritic
mice, and Mmp8-/- control mice. Male mice were used
because they showed a trend to higher arthritis severity
compared with female mice. The joints were taken 7
days after serum transfer and immediately frozen in
liquid nitrogen. Subsequent processing was done at Pro-
genika BioPharma SA (Bilbao, Spain).
Total RNA was isolated using the RNeasy Mini Kit
and the QIAshredder (Qiagen GmbH, Hilden, Ger-
many) according to the manufacturer’s instructions.
Integrity of RNA was assessed with the Agilent 2100
Bioanalyzer (Agilent Technologies, Duesseldorf, Ger-
many). Total RNA (300 ng) was subjected to cDNA
synthesis and labeling using the Whole Transcrit
cDNA synthesis and amplification kit (Affymetrix,
Santa Clara, CA, USA). This procedure involves synth-
esis of cDNA using T7-promoter-containing random
primers, which is transcribed subsequently to cRNA.
cRNA was quantified and used to generate dUTP-con-
taining cDNA. The enzymes uracyl DNA glycosylase
(UDG) and apurinic/apyramidinic endonuclease-1
(APE1) were used to fragment the dUTP-containing
cDNA. Complete fragmentation was checked in the
Bioanalyzer. Fragmented cDNA was labeled with the
terminal transferase-based Whole Transcript Terminal
Labeling kit from Affymetrix. Gene expression was
evaluated using the Mouse Gene 1.0 ST array (Affyme-
trix) that contains about 27 probes for hybridization
with each of the 28,853 mouse genome transcripts.
Quality control procedures recommended by Affyme-
trix were followed. Intensity raw data were processed
following the Robust Multichip Average method.
Expression values below background were discarded,
leaving information for 18,495 transcripts - of which
11,524 showed variable expression in at least one sam-
ple in relation with the others.
Real-time PCR analysis
Total RNA was obtained from knee joints of six Mmp8
+/+ and six Mmp8-/- male mice 7 days after serum trans-
fer, and from joints of three Mmp8+/+ and three
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Mmp8-/- control mice without arthritis, with the RNeasy
Kit and RNase-Free DNase Set (Qiagen GmbH) accord-
ing to the manufacturer’s instructions. Total RNA (500
ng) was subjected to cDNA synthesis using the RT2
First Strand Kit (SABiosciences, Frederick, MD, USA).
Quantitative real-time PCR was performed in duplicate
in a Rotor Gene 6000 thermal cycler (Corbett Research,
Cambridge, UK), using the RT2 SYBR Green/Rox qPCR
Master Mix (SABiosciences), according to the manufac-
turer’s protocol. The specific primers used in these reac-
tions are listed in Table 1.
Relative levels of gene expression were normalized to
the b-actin gene using the comparative Ct method,
where Ct is the cycle at which the amplification is initially
detected. The relative amount of mRNA from the differ-
ent genes was calculated using the formula 2-ΔΔCt, where:
ΔΔCt Ct Ct
Ct Ct
target -actin WTorKOwitharthritis
target
= −
− −
[ ]
[

 -actin WTorKOcontrols]
For wildtype and Mmp8-deficient samples without
arthritis, ΔΔCt = 0 and 20 = 1. For wildtype and knock-
out samples with arthritis, the value of 2-ΔΔCt indicates
the fold change in gene expression relative to the wild-
type and knockout controls, respectively. Melting curves
and agarose gel electrophoresis were used to assess the
amplified band.
Western blot analysis
Total proteins were obtained from ankle joints of six
Mmp8+/+ mice and six Mmp8-/- mice after 7 days of
serum transfer. Whole protein lysates (40 to 50 μg pro-
tein) were fractionated by Tris-glycine buffered 10%
SDS-PAGE, transferred to Polyvinylidene difluoride
membrane (Roche) and probed with antibodies to proki-
neticin receptor 2 (PROKR2) (Santa Cruz, Santa Cruz,
CA, USA) and b-actin (Sigma). Bound antibodies were
revealed with horseradish peroxidase-conjugated second-
ary antibodies (Santa Cruz) and the blot developed using
a SuperSignal West Femto Maximum Sensitivity Sub-
strate (Pierce, Rockford, IL, USA).
Statistical analysis
Differences between experimental groups were assessed
by repeated-measures analysis of covariance (ANCOVA)
and two-sided Mann-Whitney U tests. P < 0.05 was
considered significant. Correlation of histological para-
meters with clinical scores was determined with the
Spearman RS.
Statistical analysis of the microarray expression results
was performed with the Partek Genomics Suite v7.3.1
(Partek, Saint Louis, MO, USA) after normalization with
the Robust Multichip Average method and filtering of
values below background. Comparisons of expression
levels between sample groups were carried out with
lineal regression. Significance thresholds were consid-
ered applying a False Discovery Rate (FDR) approach or
the more conservative Bonferroni correction by the
number of independent tests. Functional classification of
genes that showed differential expression was done with
the DAVID functional annotation clustering utility
[24,25]. The default set of 13 gene annotation databases,
including three of each of the following functional cate-
gories, gene ontology, protein domains and pathways,
was used for this clustering. An enrichment score of 3.0
was taken as the threshold for reporting clusters of
genes, given that this level corresponds to significant
enrichment of the included categories according to a
FDR of 0.05. The fold change in expression levels of one
group in relation to the other was also obtained after
normalization of hybridization signals by the geometric
mean of expression levels in all of the arrays.
Results
Increased severity of arthritis in mice lacking MMP-8
To ascertain the role of MMP-8 in experimental arthri-
tis, we induced passive K/BxN arthritis in 12-generation
B6-backrossed Mmp8-deficient (Mmp8-/-) mice, and
their matched wildtype (Mmp8+/+) and heterozygous
(Mmp8+/-) littermate controls.
In a first experimental group, male and female Mmp8+/+
(n = 10), Mmp8+/- (n = 10) and Mmp8-/- (n = 10) mice
were injected intraperitoneally at day 0 and 2 with 200 μl
Table 1 Primer sets used for quantitative PCR study
Gene Band size (bp) SABiosciences catalog number EMBL accession number Reference position
IL-1b 156 PPM03109E AK168047 1,059 to 1,080
PROKR2 136 PPM39370A AF487279 851 to 870
PTX3 99 PMM03342E BC022176 1,593 to 1,612
C1QTNF3 132 PPM37236A AF246265 811 to 830
CALPAIN6 98 PMM27781A AK145116 2,029 to 2,049
MMP-3 94 PMM03673A AK148467 1,154 to 1,175
TenascinN 116 PMM30367A AF455756 4,477 to 4,499
b-Actin 154 PMM02945A AB028847 163 to 182
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K/BxN mice serum and monitored for signs of arthritis.
Evolution of arthritis was evaluated by two blinded obser-
vers on a 0 to 4 scale, as described in Materials and
methods.
An incidence of 100% of arthritis was observed in
Mmp8-/-, Mmp8+/+ or Mmp8+/- mice (Figure 1a). The
time course of arthritis was also similar in the three groups
of mice. The disease developed rapidly and the maximum
of severity was observed between 9 and 12 days. Surpris-
ingly, Mmp8-deficient mice displayed significantly higher
severity of arthritis than Mmp8+/+ and Mmp8+/- mice (P =
0.025 by repeated-measures one-way ANCOVA test) all
through the follow-up. As the severity of arthritis was
similar in Mmp8+/+ and Mmp8+/- mice, these mice were
considered a unique control group (Mmp8+).
To exclude that the system was overloaded by using 200
μl K/BxN serum and to further evaluate the observed dif-
ferences between Mmp8 control and deficient mice, a sec-
ond experimental group composed of male and female
Mmp8-/- mice (n = 17) and control mice (n = 17) was
injected intraperitoneally at day 0 and 2 with 100 μl K/
BxN serum (Figure 1b). Arthritis was monitored until day
9 and the results confirmed those previously obtained -
arthritis severity was significantly higher in Mmp8-defi-
cient mice compared with control mice (P = 0.04 by
repeated-measures one-way ANCOVA test; Figure 1b).
Increased joint inflammation and bone erosion in Mmp8-
deficient mice
To quantify joint involvement, we assessed synovial
inflammation and bone erosion in hematoxylin and
eosin stained sections of ankle joints, and cartilage
damage was evaluated in Toluidine blue and Safranin-O
stained sections. Right ankles were taken on day 9 after
serum transfer from seven Mmp8-/- and seven Mmp8+
male and female mice of the group injected intraperito-
neally with 100 μl K/BxN serum, and a blinded observer
scored the histological sections. The clinical score of the
Mmp8-/- mice was higher than in the Mmp8+ mice (P =
0.027 by Mann-Whitney U test).
Synovial inflammation was scored on a 0 to 4 scale,
corresponding to the degree of thickening of the syno-
vial lining and sublining infiltration. A significant
increase in synovial inflammation score in Mmp8-/-
mice compared with Mmp8+ mice was observed (P =
0.04 by Mann-Whitney U test; Figures 2 and 3a,d).
Changes in cellular infiltrate composition, however,
were not observed in mice lacking Mmp8 compared
with wildtype mice. Specifically, a similar rate of neutro-
phils and mononuclear cells were seen in both groups
of mice.
As shown in Figures 2 and 3c,f, bone erosion was more
marked in Mmp8-/- mice than in wildtype mice (P = 0.04
by Mann-Whitney U test). Furthermore, staining sections
for TRAP activity revealed a significantly increase of
TRAP-positive multinucleated cells in Mmp8-/- mice
compared with Mmp8+ mice (P = 0.025 by Mann-Whit-
ney U test). These cells were observed at sites of bone
erosion in both groups of mice (Figure 3c,f).
A trend to higher cartilage damage in Mmp8-/- mice
than control Mmp8+ mice was detected (Figures 3 and
4b,e), although the difference was not significant (P =
0.11 by Mann-Whitney U test). Significant correlations
between synovial inflammation, cartilage damage, bone
Figure 1 Increased arthritis severity in Mmp8-deficient mice. (a) Clinical score measured in 10 Mmp8-/- mice, 10 Mmp8+/+ mice and 10
Mmp8+/- mice after intraperitoneal injection of 200 μl K/BxN mice serum at days 0 and 2. Values expressed as mean ± standard error of the
mean (SEM); P = 0.025, by analysis of covariance (ANCOVA) test. (b) Clinical score measured in 17 Mmp8-/- mice and 17 Mmp8+ mice after
intraperitoneal injection of 100 μl K/BxN mice serum at days 0 and 2. Values expressed as mean ± SEM; P = 0.04, by ANCOVA test.
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erosion and TRAP staining with clinical scores were
observed (RS >0.64 and P < 0.017).
Overall these results suggest that MMP-8 plays a
protective role in inflammatory arthritis.
Microarray analysis
To explore the mechanisms underlying the increased
arthritis severity in Mmp8-deficient mice, we used a gen-
ome-wide microarray analysis including probes for more
than 28,000 mouse transcripts. Ankle joints from three
mice from each of the following groups were studied:
Mmp8+/+ and Mmp8-/- mice with and without arthritis.
Mice with arthritis were injected intraperitoneally on
days 0 and 2 with K/BxN mice serum, and joints were
taken 7 days after injection. Comparison of expression
levels between arthritic and nonarthritic control mice
yielded a list of about 3,200 genes that were differentially
expressed according to an FDR of 5% (2,996 genes in the
comparison among Mmp8+/+ mice and 3,407 genes in
the Mmp8-/- comparison), or about 1,000 genes accord-
ing to the more stringent FDR 1% threshold (Table 2).
These lists were largely concordant in the two
Figure 2 Increased joint inflammation and bone erosion in
mice lacking Mmp8. Histologic scores of synovial inflammation (SI),
cartilage damage (CD), bone erosion (BE) and tartrate-resistant acid
phosphatase (TRAP) staining of ankle sections of Mmp8+ mice (n =
8) and Mmp8-/- mice (n = 7) at day 9 after intraperitoneal arthritis
induction. Values expressed as mean ± standard error of the mean;
*P < 0.05 by two-sided Mann-Whitney U test.
Figure 3 Higher synovial inflammation and bone erosion in arthritic joints of Mmp8-deficient mice than control mice. Representative
sections of ankle joints of Mmp8-/- mice (a) to (c) and Mmp8+ mice (d) to (f) 9 days after intraperitoneal injection of K/BxN serum. More severe
inflammation and pannus formation (arrows) were observed on hematoxylin and eosin stained sections from Mmp8-deficient mice (a) compared
with control mice (d). More severe loss of proteoglycans indicated by destained cartilage was observed on Safranin-O stained sections from
Mmp8-/- mice (b) compared with Mmp8+ mice (e). Increased tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclast-like
cells (arrows) were observed at sites of bone erosions on sections stained for TRAP activity from Mmp8-deficient mice (c) compared with control
mice (f).
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independent comparisons, as assessed by the fact that
most genes differently expressed in Mmp8+/+ mice were
also differently expressed in Mmp8-/- mice. In fact, direct
comparison of arthritic Mmp8+/+ mice with arthritic
Mmp8-/- mice did not show any significant difference.
We therefore conducted other types of analyses. First,
we compared the functional groups of differentially
expressed genes modified in both groups of arthritic
mice, only in arthritic Mmp8+/+ mice and only in
Mmp8-/- mice. The 660 genes that were modified both
in Mmp8+/+ mice and Mmp8-/- mice, according to a
FDR 0.01 threshold, could be grouped into eight clusters
with an enrichment score over 3.0 (Figure 4). These
clusters included some that are more structurally
defined and others that are more related with cellular or
biological pathways. The same type of analysis was also
carried out for the sets of genes that were different only
in the Mmp8+/+ arthritic mice according to the same
FDR 0.01 criteria. There were 334 genes in this class
and they were grouped into five clusters of annotations
with an enrichment score over 3.0. These five clusters
were a subgroup of the eight clusters that were modified
in both groups of arthritic mice. The only three clusters
missing here were the cluster of epidermal growth fac-
tor-like domain proteins and the two last clusters: the
one grouping cell migration and motility genes, and the
one containing transmembrane proteins. The genes
whose expression was significantly modified in arthritic
Mmp8+/+ mice and not in arthritic Mmp8-/- mice were
therefore largely from the same functional classes as the
genes that were modified in both types of mice.
Table 2 Number of differentially expressed genes
Mice Control versus rheumatoid arthritis
FDR <0.05 FDR <0.01 Pcorr <0.05
Mmp8+/+ 2,996 994 77
Mmp8-/- 3,407 1,046 52
Mmp8+/+ and Mmp8-/- 2,136 660 40
Mmp8+/+ exclusive 860 334 37
Mmp8-/- exclusive 1,271 386 12
No differences were found between arthritic Mmp8+/+ and arthritic Mmp8-/-
mice. FDR, false discovery rate.
Figure 4 Clustering of differentially expressed genes. The DAVID utility [24,25] was used to cluster differentially expressed genes according
to a false discovery rate 0.01 threshold, in both Mmp8+/+ and Mmp8-/-arthritic mice, exclusive arthritic Mmp8+/+ mice and exclusive arthritic
Mmp8-/- mice. The functional description and the number of genes with enrichment score (E. score) >3.0 are shown.
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A similar analysis with the 386 genes that were modi-
fied only in arthritic Mmp8-/-mice gave very different
results. No single cluster of genes showed an enrich-
ment score over 3.0, and only two clusters showed a
score over 2.0. This indicates that the modified genes
specific of arthritis in the Mmp8-/- mice are very varied
and difficult to group. The pattern of genes that were
differentially regulated in Mmp8+/+ mice and Mmp8-/-
mice are therefore very different: the genes regulated
specifically in arthritic Mmp8-/- mice are similar in
number but much more diverse functionally.
The lack of any clearly defined functional class of
genes specifically modified in arthritic Mmp8-/- mice
made it impossible to focus on them to try to discern
important factors in the differential arthritis phenotype.
We decided to concentrate instead on the genes that,
having a most clearly changed expression with arthritis,
were also most differentially affected in Mmp8+/+ and
Mmp8-/- mice. We selected the 86 nonredundant genes
that were different between arthritic and control mice in
the comparison of either Mmp8+/+ mice or Mmp8-/-
mice according to the very conservative Bonferroni-cor-
rected threshold of P = 0.05. We obtained the fold
change ratios between their respective comparisons.
Genes with fold change ratios higher than 1.35 and
lower than 0.75 were considered interesting (Table 3).
That is, differences between arthritic Mmp8-/- mice and
their controls were compared with differences between
arthritic Mmp8+/+ mice and their controls, and the most
extreme fold change ratios were selected. Seven out of
29 genes were chosen for confirmatory real-time PCR
experiments given their interest in inflammation, auto-
immunity or arthritis.
The data discussed in this publication have been
deposited in NCBI’S Gene Expression Omnibus [26] and
are accessible through the GEO Series accession number
[GEO:GSE22971] [27].
Induction of IL-1b, PROKR2 and PTX3 in arthritic Mmp8-
deficient mice
To corroborate the results obtained by the microarray
analysis, real-time RT-PCR experiments were performed
in arthritic joints from six other Mmp8-deficient mice
and six wildtype mice treated in the same way.
Increased mRNA expression of IL-1b, PROKR2 and pen-
traxin-3 (PTX3) was found in arthritic Mmp8-/- mice
compared with wildtype mice (P = 0.035, P = 0.032 and
P = 0.028, respectively; Figure 5a). Real-time PCR did
not, however, confirm the expression changes observed
in CALPAIN 6, MMP-3, C1QTNF3 and TenascinW in
Mmp8-deficient mice compared with wildtype mice
(data not shown).
Increased production of IL-1b and PTX3 was verified
by ELISA assay (Figure 5b,c), and results showed a
significant increase of both proteins in joints from
Mmp8-/- mice compared with Mmp8+/+ mice (P = 0.031
and P = 0.017, respectively). PROKR2 production was
assessed by western blot and is shown in Figure 6a,b. As
expected, PROKR2 levels were significantly higher in
joints from Mmp8-deficient than in control male mice
(P = 0.031).
Discussion
Accumulated evidence indicates that MMPs are involved
in the cartilage destruction observed in RA [1-4,7];
MMP inhibitors are thereby of special interest for the
treatment of RA. Results from clinical trials of MMP
inhibitors in RA have not been encouraging, however,
probably due to lack of specificity of such inhibitors
Table 3 Genes with the most discordant changes in
expression in Mmp8+/+ and Mmp8-/-arthritic mice
Gene Fold change: CRL Mmp8-/-
vs. RA Mmp8-/- (A)
Fold change: CRL
Mmp8+/+ vs. RA
Mmp8+/+ (B)
Ratio
A/B
Anpep 2.107 3.766 0.559
Arsi 3.440 4.685 0.734
Aspa 0.289 0.195 1.481
C1qtnf3 5.773 8.349 0.691
Capn6 5.503 11.324 0.485
Ces3 0.050 0.074 0.682
Csgalnact1 4.318 5.906 0.731
Ddefl1 1.411 2.010 0.702
Fbln2 2.254 3.128 0.720
Gltd5d1 1.411 2.158 0.654
Grb10 1.639 2.421 0.677
H19 3.154 5.834 0.541
Ifitm1 2.100 4.232 0.496
Il1b 5.014 3.711 1.351
Itga5 2.184 3.079 0.709
Mmp3 27.264 41.104 0.663
Nt5dc2 3.532 4.891 0.722
P4ha3 6.826 9.504 0.718
Postn 2.949 4.571 0.645
Prokr2 4.791 3.527 1.358
Ptgfrn 1.705 2.407 0.708
Ptx3 6.117 4.493 1.361
Rentla 0.031 0.043 0.709
Sfrp1 8.278 11.900 0.696
Slc39a14 5.882 7.949 0.739
Sult1a1 0.251 0.181 1.379
Syne2 0.590 0.335 1.759
TenascinN 3.653 5.793 0.631
Tpd52 2.410 1.781 1.353
Genes with the most discordant changes (<0.75 or >1.35) in expression in
Mmp8+/+ and Mmp8-/-arthritic mice in relation to their respective nonarthritic
controls (selected from arthritis-associated genes according to Bonferroni-
corrected P < 0.01). Bold genes were chosen for confirmatory real-time PCR.
CRL, control; RA, rheumatoid arthritis.
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Figure 5 Increased IL-1b, PTX-3 and PROKR2 mRNA and protein levels in mice lacking Mmp8. (a) IL-1b, pentraxin-3 (PTX-3) and
prokineticin receptor 2 (PROKR2) mRNA levels were measured by quantitative real-time PCR in arthritic joints of Mmp8-/- mice (n = 6) and Mmp8
+/+ mice (n = 6) at day 7 after intraperitoneal serum injection. Levels of IL-1b (b) and PTX-3 (c) proteins were measured by ELISA in extracts
from arthritic joints of mice at day 7 after intraperitoneal serum injection. Values expressed as mean ± standard error of the mean; *P < 0.05, by
two-sided Mann-Whitney U test.
Figure 6 Increased PROKR2 expression in Mmp8-deficient mice. Protein expression of prokineticin receptor 2 (PROKR2) was determined by
western blot in arthritic joints of six Mmp8-/- mice and six Mmp8+/+ mice at 7 days after arthritis induction. Densitometric analysis of PROKR2
and that normalized with the intensity of actin is shown. (a) Data represent mean ± standard error of the mean; *P < 0.05, by Mann-Whitney U
test. (b) Representative blot.
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[28,29]. In fact, analyses of several MMPs in animal
models have shown either [9-11] exacerbation or reduc-
tion of arthritis severity depending on the MMP ana-
lyzed. This indicates that specific MMPs could have
either a promoting or a protective role in arthritis
pathogenesis. Knowledge of the role of specific MMPs
in the pathogenesis of arthritis therefore seems pivotal
to obtain successful inhibitors for treatment. In the pre-
sent study, we have investigated the impact of lack of
Mmp8 in the K/BxN serum-transfer arthritis model.
The advantages of this transfer model with respect to
other arthritis models is its 100% penetrance, early
onset, rapid development of osteolytic lesions and its
MHC independence. Clinical features and histopathol-
ogy are very similar to human RA. Another characteris-
tic of the K/BxN transfer model is that it allows us to
focus on the effector phase mechanisms of arthritis that
are dependent on neutrophils, macrophages, mast cells,
and inflammatory mediators, especially IL-1b, but inde-
pendent of T cells and B cells.
We have found that the absence of Mmp8 increased
the severity of arthritis without noticeably affecting its
time course, either at its onset or at its spontaneous
remission. The aggravated clinical course of arthritis
was accompanied by exacerbated synovial inflammation
and bone erosion. These effects were associated with
modified expression of a varied array of genes, includ-
ing overexpression of IL-1b, PTX3 and PROKR2 in
arthritic joints. Surprisingly, despite the known collage-
nolytic activity of Mmp-8, its absence did not protect
from cartilage damage but a trend to increased damage
was observed compared with Mmp8 wildtype mice.
This finding may indicate that other Mmps could com-
pensate for its absence. These data indicate that Mmp-
8 plays a protector role against arthritis in this model.
This effect is consistent with the previously reported
effect of Mmp-8 absence in other inflammation models
such as OVA-induced airway inflammation [17], che-
mically-induced skin carcinomas [19] and skin wound
healing [16], in which the absence of Mmp-8 increased
the severity of these pathologies and delayed wound
healing. In these studies, disease aggravation was linked
to increased neutrophil accumulation in the mice lack-
ing Mmp8. In our work, we did not observe differences
in cellular infiltrate composition between Mmp8 con-
trol and deficient mice, suggesting that mechanisms
involved in the Mmp-8 regulation of inflammation are
complex and include its effect in other aspects of
inflammation as shown by our expression studies. It is
possible that differences between models depend on
the nature of the inflammatory stimulus or of the tis-
sue affected.
To elucidate the mechanisms behind arthritis aggrava-
tion in Mmp8-/- mice, we have investigated the gene
expression profile in Mmp8-sufficient and Mmp8-defi-
cient mice with and without arthritis using microarray
technology. There was a wide array of genes that chan-
ged expression in arthritic mice. Most were coincident
in Mmp8-sufficient and Mmp8-deficient mice, and they
can be grouped in functional categories that are congru-
ent with current knowledge of arthritis mechanisms.
The functional spread of the genes whose expression
was only modified in the arthritic Mmp8-/- mice con-
trasted with the clustering in five functional categories
of the genes significantly modified only in the arthritic
Mmp8 wildtype mice, despite being similar in number.
This result is consistent with the lack of any clearly dif-
ferent phenotype in the histological analysis and has
been taken into consideration to interpret the analyses
of individual genes. To select genes for detailed analysis,
we decided to focus on the genes that with high likeli-
hood were differentially expressed with respect to arthri-
tis and the presence of Mmp8. After selection of a
group of seven genes, we found an increased expression
of IL-1b, PTX3 and PROKR2 in arthritic joints from
Mmp8-deficient mice compared with wildtype mice that
were confirmed by real-time PCR assays. The corre-
sponding increase in protein expression was validated by
ELISA and western blot.
IL-1b is highly expressed in the synovium of RA
patients and plays a crucial role in production of inflam-
matory mediators and articular damage [2,30]. This
cytokine’s functional relevance has been demonstrated
in several animal models, including the K/BxN model
[30-36]. Results of these studies indicate that the
increased IL-1b expression observed in Mmp8-deficient
mice can contribute to the higher clinical score, synovial
inflammation, osteoclast activity and bone erosion found
in these mice.
PTX3 is the prototypic member of the long pentraxin
family of acute phase reactants. PTX3 rapidly increases
in serum during endotoxic shock, inflammation and
infections [37]. A possible role of this protein in poten-
tiating inflammation has been reported in a model of
intestinal injury by ischemia/reperfusion in which
PTX3 transgenic mice showed exacerbated inflamma-
tory response and increased lethality [38]. Also, mice
lacking PTX3 displayed reduced tissue inflammation
and increased survival rates [39]. Our results showed
an increased PTX3 expression in mice lacking Mmp8
compared with wildtype mice, where it was also
increased, indicating that PTX3 upregulation could
have contributed to the higher arthritis severity in the
knockout mice. This result suggests that the accumula-
tion of PTX3 in the synovial fluid of RA patients after
being produced by synoviocytes and synovial endothe-
lial cells [40] can be also a contributor to the inflam-
mation process.
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PROKR2 is a seven-transmembrane coupled G-protein
receptor that binds prokineticin-2. PROKR2 is highly
expressed in the bone marrow, and in neutrophils,
monocytes and dendritic cells [41]. Signaling through
this receptor induces survival, differentiation and activa-
tion of granulocytic and monocytic lineages [42]. The
higher expression of PROKR2 found in the arthritic
joints from Mmp8-deficient mice could therefore have
contributed to the increased inflammatory infiltration
observed in them.
Changes in the expression of these three genes exem-
plify different ways in which the lack of MMP-8 led to
an aggravation of arthritis: promotion of inflammation
by IL-1b and other molecules like PTX3, induction of
maturation and activation of osteoclasts by IL-1b and
PROKR2, and enhanced inflammatory infiltrate by IL-1b
and possibly PROKR2 - however, other contributing
mechanisms are possible as only a fraction of the genes
with possible differential expression were analyzed. Simi-
lar analysis in other models of inflammation will help to
unravel the many ways in which MMP-8 seems to pro-
tect against inflammation.
Conclusions
The present study indicates that MMP-8 protects
against inflammatory synovitis and bone erosion in the
K/BxN serum-transfer arthritis model. Expression analy-
sis indicates that protection is due to changes in multi-
ple genes belonging to different functional categories.
Three of these genes have been validated exemplifying
the involved pathways: IL-1b, PTX3 and PROKR2.
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